Although very strong today SRPT has stuggled to break above the $138 level , order in place to capture a possible break out.
In a long trade for some time since the sellf off, so if it fails at $138 time to cach out.
Way too much in one day, bought some puts this afternoon, will flip them at the gap support, though I think it will go lower and do an inverted H&S pattern
Entry level $132.59 = Target price $138.82 = Stop loss $130.66
7&12 MA's cross imminent.
Sarepta Therapeutics could very well continue to surge on the FDA approval.
SRPT: Sarepta Therapeutics, Inc.
2019-12-12 18:19:20
Sarepta Therapeutics Announces FDA Approval of VYONDYS 53™ (golodirsen) Injection for the Treatment of Duchenne Muscular Dystrophy (DMD) in Patients Amenable to Skipping Exon 53
Sarepta Therapeutics (NASDAQ:SRPT) +23.4% after-hours on news the Food and Drug Administration granted accelerated approval to the company's Vyondys 53 (golodirsen) injection to treat a rare Duchenne muscular dystrophy mutation.
In making its decision, the FDA says it considered the potential risks associated with the drug, the life-threatening and debilitating...
Has been a very profitable trade so far from the bottom and we now look to complete the gap fill.
Entry level $113 - Target price $ 120 = Stop loss $110.43
Hopefully you followed our previous winning trades on SRPT and having banked some nice gains.
The next trade setup is to trade the gap with a entry level @ $16.85 and a gap fill target @ $119.
Local rare disease drugmaker Sarepta Therapeutics Inc. is expanding its efforts in the gene therapy field, signing a deal this week with a North Carolina startup to...
Entry level $98 = Target price $125 (long term) $108 (short term)
Looks like a strong reversal setup, the macd is about to cross while the histogram is also in the process of turning green.
Bullish 7&12 MA cross imminent.
Resistance as per the chart.
Earnings article by Barrons.
Earnings at the biotech firm Sarepta Therapeutics fell short of expectations in the...
Nomura $230 price target
Sarepta analyst commentary at Nomura Instinet Sarepta has 'signficant upside catalysts ahead,' says Nomura Instinet. Nomura Instinet analyst Christopher Marai sees "significant upside catalysts ahead into mid-2020" for Sarepta Therapeutics. Ahead of the company's Q3 results on November 7 he keeps a Buy rating on the shares with a $230...
Possible short term breakout in SRPT above $89 with $96 as a 1-2-1 Fibonacci extension target.
This may be a contrarian trade but maybe sentiment and expectations are so poor it presents a good short squeeze opportunity.
Short interest is high at 21% and increased since the July disappointment.
The average analysts price target is $186 and a BUY rating which is a...
AVERAGE ANALYSTS PRICE TARGET $190
AVERAGE ANALYSTS RECOMMENDATION BUY
HIGH 20% SHORT INTEREST.
Sarepta Therapeutics, Inc. is a commercial-stage biopharmaceutical company, which is engaged in the discovery and development of therapeutics for the treatment of rare diseases. The company was founded on July 22, 1980 and is headquartered in Cambridge, MA.
Technically the stock has broken down at a horrendous pace, many technical supports are now broken and the MA's are now a hindrance not a help.
Price history support is now the bulls last stance.
SPRT near to strong weekly support level. possibly buy. wait for confirmation. I cant believe the Food and Drug Administration rejected the latest Duchenne muscular dystrophy drug, dubbed golodirsen. This could get ugly. Watching for a bounce and keeping an eye on the overall market as well. also watching this one .
